Keeler THomas Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 34.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,703 shares of the company’s stock after selling 3,969 shares during the quarter. Keeler THomas Management LLC’s holdings in Johnson & Johnson were worth $1,275,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of JNJ. BlackRock Inc. raised its stake in Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock valued at $31,231,193,000 after buying an additional 2,688,798 shares in the last quarter. Moneta Group Investment Advisors LLC raised its stake in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC raised its stake in Johnson & Johnson by 1.6% during the first quarter. Geode Capital Management LLC now owns 48,707,500 shares of the company’s stock valued at $7,532,525,000 after buying an additional 748,917 shares in the last quarter. Morgan Stanley raised its stake in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 15.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after buying an additional 3,849,148 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.
Analyst Ratings Changes
JNJ has been the topic of several research reports. Stifel Nicolaus upped their price objective on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Royal Bank of Canada started coverage on Johnson & Johnson in a report on Wednesday, October 4th. They set an “outperform” rating and a $178.00 target price for the company. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, September 29th. Finally, TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.06.
Insider Buying and Selling at Johnson & Johnson
In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $158.53 on Tuesday. The stock has a fifty day moving average price of $164.12 and a two-hundred day moving average price of $162.46. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market cap of $412.01 billion, a P/E ratio of 32.09, a PEG ratio of 3.19 and a beta of 0.55. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the company posted $2.59 EPS. Research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- 10 Best Airline Stocks to Buy
- MarketBeat ‘Stock of the Week’ Ford, Strike Presents Opportunity
- Investing in the Best Airline Stocks
- Healthcare Giant Outperforms: A Healthy Dose of Market Resilience
- What is the Euro STOXX 50 Index?
- 5 Reasons Rivian is a Buy on Shaken Investor Sentiment
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
